Core Insights - RxSight, Inc. reported record highs in Light Delivery Device (LDD) sales and Light Adjustable Lens (LAL) procedures during Q4 2024, significantly exceeding initial revenue guidance for the year [3][4] - The company serves approximately 15% of cataract surgeons in North America, with LAL procedures representing over 10% of the premium intraocular lens (IOL) market in the region [3] - RxSight plans to expand into international markets in Asia and Europe while continuing to innovate its RxSight system [3] Preliminary Financial Results - Preliminary unaudited revenue for Q4 2024 is expected to be around $40.2 million, reflecting a 41% increase year-over-year, driven by the sale of 29,069 LALs, a 61% increase in procedure volume compared to Q4 2023, and 83 LDDs sold, bringing the total installed base to 971 [7] - For the full year 2024, preliminary revenue is projected at approximately $139.9 million, a 57% increase from the previous year, supported by the sale of 98,055 LALs, a 79% increase in procedure volume, and 305 LDDs sold [7] 2025 Guidance - The company anticipates full-year 2025 revenue between $185.0 million and $197.0 million, indicating growth of approximately 32% to 41% over 2024 [4] - Expected gross profit margin for 2025 is projected to be in the range of 71% to 73% [4] - Operating expenses for 2025 are estimated to be between $165.0 million and $170.0 million, which includes non-cash stock-based compensation expenses of $22.0 million to $25.0 million [4]

Core Viewpoint - RxSight, Inc. is set to participate in the J.P. Morgan Healthcare Conference, highlighting its commitment to advancing ophthalmic medical devices for cataract surgery patients [1][2]. Company Overview - RxSight, Inc. specializes in ophthalmic medical devices aimed at providing customized vision solutions for patients post-cataract surgery [3]. - The company's flagship product, the RxSight Light Adjustable Lens system, is the first and only commercially available intraocular lens technology that can be adjusted after surgery, allowing for tailored vision correction [3]. Event Participation - Management will present at the J.P. Morgan Healthcare Conference on January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time, with a live and archived webcast available for interested parties [2].

Core Insights - The article emphasizes the importance of disciplined risk management in investment strategies, advocating for a barbell approach that allocates 90% to safe assets and 10% to high-growth opportunities [1] DCF Model Assumptions - The valuation model assumes free cash flow will grow at a constant annual rate over the next eight years, with each year's projected cash flow discounted back to present value using a fixed discount rate derived from the Capital Asset Pricing Model (CAPM) [1] - A terminal value is calculated by projecting free cash flow into the ninth year, assuming it continues to grow at the same rate, and applying a perpetual growth rate using the Gordon Growth Model [1] - Key assumptions include constant growth and discount rates over time, with the discount rate exceeding the perpetual growth rate to ensure a finite terminal value [1]

Investors might want to bet on RxSight, Inc. (RXST) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ch ...

RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpassed consensus ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 Identification No.) (I.R.S.Employer (State or other jurisdiction of incorporationororganization) RxSIGHT, INC. (Exact N ...

Exhibit 99.1 RXSIGHT, INC. REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) – November 7, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights • Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: • The s ...

ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference cal ...

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference - Fireside Chat: Wednesday, September 4, 2024, at 9:15 a.m. ET in New York City, NY Wells Fargo 2024 Healthcare Conference - Fireside Chat: Thur ...

Core Insights - RxSight, Inc. is a pioneering medical technology company focused on transforming cataract surgery with its innovative Light Adjustable Lens (LAL) system, which is the first FDA-approved premium intraocular lens that allows for postoperative adjustments [3][4] - The global cataract devices market is valued at $13 billion annually and is projected to grow to $20 billion by 2032, with RxSight positioned to capitalize on this growth due to its unique product offering [3][4] - The company reported a significant revenue increase of 68% in Q2 2024, driven by a 92% rise in Light Adjustable Lens sales, indicating strong market penetration and demand for its innovative solutions [5][6] Industry Overview - Cataracts affect approximately 50% of individuals by age 60, leading to a substantial market for cataract surgeries, with 31 million surgeries performed globally in 2023 [3] - The premium intraocular lens market, which represents about 21% of U.S. cataract surgeries, generated approximately $780 million in revenue in 2023 and is expected to grow at a CAGR of 9.5%, reaching $1.3 billion by 2028 [3] Company Performance - In Q2 2024, RxSight achieved total revenue of $34.9 million, with gross profit reaching $24.3 million, reflecting a gross profit margin of 69.5% [5][6] - Operating expenses increased to $32.6 million, primarily due to investments in expanding the Light Delivery Device installed base and supporting increased LAL sales volume [6] - The company has raised its full-year revenue guidance to $139 million to $140 million, indicating a growth of 56% to 57% compared to 2023 [6] Competitive Advantage - The LAL system offers unique postoperative adjustability, allowing for customized vision correction, which is not available with traditional fixed-power premium IOLs [4][9] - Clinical trials show that 70% of LAL patients achieved 20/20 vision without glasses, compared to only 40% with other premium IOLs, highlighting superior outcomes and lower incidences of side effects [4] Valuation and Market Sentiment - The stock is considered undervalued with a fair value estimated at $76, indicating potential upside for investors [7] - The mean sell-side analyst price target is $72, suggesting a 51% upside potential from current levels [8] - The company has received a Strong Buy rating from SA Quant, reflecting positive market sentiment following its impressive Q2 earnings report [8][9]